Filter News
Area of Research
- Advanced Manufacturing (1)
- Biological Systems (1)
- Biology and Environment (26)
- Clean Energy (23)
- Computational Biology (2)
- Computational Engineering (1)
- Fusion and Fission (7)
- Fusion Energy (7)
- Isotopes (25)
- Materials (23)
- Materials for Computing (6)
- National Security (5)
- Neutron Science (15)
- Nuclear Science and Technology (17)
- Nuclear Systems Modeling, Simulation and Validation (1)
- Supercomputing (26)
News Topics
- (-) Advanced Reactors (34)
- (-) Biomedical (58)
- (-) Coronavirus (46)
- (-) Isotopes (51)
- 3-D Printing/Advanced Manufacturing (119)
- Artificial Intelligence (91)
- Big Data (51)
- Bioenergy (91)
- Biology (98)
- Biotechnology (22)
- Buildings (56)
- Chemical Sciences (62)
- Clean Water (29)
- Climate Change (98)
- Composites (26)
- Computer Science (185)
- Critical Materials (25)
- Cybersecurity (35)
- Decarbonization (78)
- Education (4)
- Element Discovery (1)
- Emergency (2)
- Energy Storage (108)
- Environment (194)
- Exascale Computing (37)
- Fossil Energy (5)
- Frontier (42)
- Fusion (53)
- Grid (61)
- High-Performance Computing (84)
- Hydropower (11)
- Irradiation (3)
- ITER (7)
- Machine Learning (47)
- Materials (143)
- Materials Science (138)
- Mathematics (7)
- Mercury (12)
- Microelectronics (2)
- Microscopy (51)
- Molten Salt (8)
- Nanotechnology (60)
- National Security (60)
- Net Zero (13)
- Neutron Science (130)
- Nuclear Energy (105)
- Partnerships (41)
- Physics (59)
- Polymers (33)
- Quantum Computing (32)
- Quantum Science (67)
- Renewable Energy (2)
- Security (24)
- Simulation (45)
- Software (1)
- Space Exploration (25)
- Statistics (3)
- Summit (57)
- Sustainable Energy (124)
- Transformational Challenge Reactor (7)
- Transportation (95)
Media Contacts
As the rise of antibiotic-resistant bacteria known as superbugs threatens public health, Oak Ridge National Laboratory’s Shuo Qian and Veerendra Sharma from the Bhaba Atomic Research Centre in India are using neutron scattering to study how an antibacterial peptide interacts with and fights harmful bacteria.
OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.
While studying the genes in poplar trees that control callus formation, scientists at Oak Ridge National Laboratory have uncovered genetic networks at the root of tumor formation in several human cancers.
OAK RIDGE, Tenn., Jan. 31, 2019—A new electron microscopy technique that detects the subtle changes in the weight of proteins at the nanoscale—while keeping the sample intact—could open a new pathway for deeper, more comprehensive studies of the basic building blocks of life.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
A team of scientists, led by University of Guelph professor John Dutcher, are using neutrons at ORNL’s Spallation Neutron Source to unlock the secrets of natural nanoparticles that could be used to improve medicines.
Physicists turned to the “doubly magic” tin isotope Sn-132, colliding it with a target at Oak Ridge National Laboratory to assess its properties as it lost a neutron to become Sn-131.
Scientists at the Department of Energy’s Oak Ridge National Laboratory used neutrons, isotopes and simulations to “see” the atomic structure of a saturated solution and found evidence supporting one of two competing hypotheses about how ions come
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.